185 related articles for article (PubMed ID: 10534139)
21. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
22. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
23. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
24. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders.
Subramaniam S
Clin Exp Hypertens; 1999; 21(1-2):121-36. PubMed ID: 10052648
[TBL] [Abstract][Full Text] [Related]
25. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
[TBL] [Abstract][Full Text] [Related]
27. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
Teter ML
Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
[No Abstract] [Full Text] [Related]
28. Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.
Horikoshi H; Hashimoto T; Fujiwara T
Prog Drug Res; 2000; 54():191-212. PubMed ID: 10857389
[TBL] [Abstract][Full Text] [Related]
29. [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Brogard JM; Neyrolles N; Andres E; Blicklé JF
Rev Med Interne; 1999 Aug; 20 Suppl 3():371s-378s. PubMed ID: 10480188
[TBL] [Abstract][Full Text] [Related]
30. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
31. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
Cominacini L; Garbin U; Fratta Pasini A; Campagnola M; Davoli A; Foot E; Sighieri G; Sironi AM; Lo Cascio V; Ferrannini E
Diabetes; 1998 Jan; 47(1):130-3. PubMed ID: 9421387
[TBL] [Abstract][Full Text] [Related]
32. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
33. Effects of thiazolidinediones on cardiovascular risk factors.
Gouda BP; Asnani S; Fonseca VA
Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
[TBL] [Abstract][Full Text] [Related]
34. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
35. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
36. [Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Isshiki K; Haneda M; Koya D; Kikkawa R
Nihon Rinsho; 2000 Feb; 58(2):440-5. PubMed ID: 10707573
[TBL] [Abstract][Full Text] [Related]
37. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
38. Where thiazolidinediones will fit.
Reasner CA
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S30-5. PubMed ID: 11921436
[TBL] [Abstract][Full Text] [Related]
39. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
40. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Samraj GP; Kuritzky L; Quillen DM
Hosp Pract (1995); 2000 Jan; 35(1):123-4, 129-32. PubMed ID: 10645993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
